Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors

Journal of Clinical Investigation

Volumn 114, Issue 9, 2004, Pages 1317-1325

  Nakayama, Takayuki ^a   Yao, Lei ^a   Tosato, Giovanna ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; VASCULOTROPIN A; ANGIOPOIETIN 2; COLLAGEN; CYTOKINE; LAMININ; MATRIGEL; PROTEOGLYCAN; RECOMBINANT PROTEIN; RNA;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACELLULAR MATRIX; HUMAN; MAST CELL; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DRUG COMBINATION; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CYTOKINES; DRUG COMBINATIONS; EXTRACELLULAR MATRIX; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LAMININ; MAST CELLS; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PLASMACYTOMA; PROTEOGLYCANS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85047691124     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI22089     Document Type: Article

References (61)

1. Balkwill, F., and Mantovani, A. 2001. Inflammation and cancer: back to Virchow? Lancet. 357:539-545.
2. Coussens, L.M., and Werb, Z. 2002. Inflammation and cancer. Nature. 420:860-867.
3. Andersen, A.O., Wax, J.S., and Potter, M. 1985. Differences in the peritoneal response to pristane in BALB/cAnPt and BALB/cJ mice. Curr. Top. Microbiol. Immunol. 122:242-253.
4. Potter, M. 2003. Neoplastic development in plasma cells. Immunol Rev. 194:177-195.
5. Lennard-Jones, J.E., Melville, D.M., Morson, B.C., Ritchie J.K., and Williams, C.B. 1990. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut. 31:800-806.
6. Ernst, P.B., and Pappo, J. 2000. Preventive and therapeutic vaccines against Helicobacter pylori: current status and future challenges. Curr. Pharm. Des. 6:1557-1573.
7. Tsukuma, H., et al. 1993. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N. Engl. J. Med. 328:1797-1801.
8. Baron, J.A., and Sandler, R.S. 2000. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu. Rev. Med. 51:511-523.
9. Westphal, J.R. 1891. Über mastzellen. In Farbenalytische Untersuchungen. P. Ehrich, editor. Hirschwald. Berlin, Germany. 17-41.
10. Kessler, D.A., Langer, R.S., Pless, N.A., and Folkman, J. 1976. Mast cells and tumor angiogenesis. Int. J. Cancer. 18:703-709.
11. Ribatti, D., et al. 2001. The role of mast cells in tumour angiogenesis. Br. J. Haematol. 115:514-521.
12. Starkey, J.R., Crowle, P.K., and Taubenberger, S. 1988. Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int. J. Cancer. 42:48-52.
13. Dethlefsen, S.M., Matsuura, N., and Zettet, B.R. 1994. Mast cell accumulation at sites of murine tumor implantation: implications for angiogenesis and tumor metastasis. Invasion Metastasis. 14:395-408.
14. Coussens, L.M., et al. 1999. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13:1382-1397.
15. Coussens, L.M., Tinkle, C.L., Hanahan, D., and Werb, Z. 2000. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 103:481-490.
16. Egeblad, M., and Werb, Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nat. Ref. Cancer. 2:161-174.
17. Feoktistov, I., Ryzhov, S., Goldstein, A.E., and Biaggioni, I. 2003. Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ. Res. 92:485-492.
18. Shaughnessy, J.D., Jr., and Barlogie, B. 2003. Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling. Immunol. Rev. 194:140-163.
19. Vanderkerken, K., Asosingh, K., Croucher, P., and Van Camp, B. 2003. Multiple myeloma biology: lessons from the 5TMM models. Immunol. Rev. 194:196-206.
20. Ribatti, D., et al. 1999. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br. J. Cancer. 79:451-455.
21. Vacca, A., Ribatti, D., Roccaro, A.M., Frigeri, A., and Dammacco, F. 2001. Bone marrow angiogenesis in patients with active multiple myeloma. Semin. Oncol. 28:543-550.
22. Ferrara, N., Gerber, H.P., and LeCouter, J. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669-676.
23. Carmeliet, P. 2003. Angiogenesis in health and disease. Nat. Med. 9:653-660.
24. Thurston, G., et al. 1999. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 286:2511-2514.
25. Gurish, M.F., and Austen, K.F. 2001. The diverse roles of masr cells. J. Exp. Med. 194:F1-F5.
26. Norrby, K. 2002. Mast cells and angiogenesis. APMIS. 110:355-371.
27. Davis, S., et al. 1996. Isolation of angiopoietin-1, a ligand for the T1E2 receptor, by secretion-trap expression cloning. Cell. 87:1161-1169.
28. Holash, J., et al. 1999. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 284:1994-1998.
29. Davis, S., et al. 2003. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat. Struct. Biol. 10:38-44.
30. Hattori, K., et al. 2001. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 193:1005-1014.
31. Stoeltzing, O., et al. 2003. Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res. 63:3370-3377.
32. Suri, C., et al. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 87:1171-1180.
33. Sato, T.N., et al. 1995. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature. 376:70-74.
34. Thurston, G., et al. 2000. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat. Med. 6:460-463.
35. Li, J.J., Huang, Y.Q., Basch, R., and Karpatkin, S. 2001. Thrombin induces the release of angiopoietin-1 from platelets. Thromb. Haemost. 85:204-206.
36. Metheny-Barlow, L.J., and Li, L.Y. 2003. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res. 13:309-317.
37. Takahama, M., et al. 1999. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin. Cancer Res. 5:2506-2510.
38. Brown, L.F., Dezube, B.J., Tognazzi, K., Dvorak, H.F., and Yancopoulos, G.D. 2000. Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am. J. Pathol. 156:2179-2183.
39. Giuliani, N., et al. 2003. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood. 102:638-645.
40. Uneda, S., et al. 2003. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica. 88:113-115.
41. Potter, M., and Boyce, C.R. 1962. Induction of plasma-cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature. 193:1086-1087.
42. Potter, M., Wax, J.S., Anderson, A.O., and Nordan, R.P. 1985. Inhibition of plasmacytoma development in BALB/c mice by indomethacin. J. Exp. Med. 161:996-1012.
43. Nordan, R.P., and Potter, M. 1986. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science. 233:566-569.
44. Kishimoto, T. 1989. The biology of interleukin-6. Blood. 74:1-10.
45. Suematsu, S., et al. 1992. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 89:232-235.
46. Gomi, K., Zhu, F.G., and Marshall, J.S. 2000. Prostaglandin E2 selectively enhances the IgE-mediated production of IL-6 and granulocyte-macrophage colony-stimulating factor by mast cells through an EP1/EP3-dependent mechanism. J. Immunol. 165:6545-6552.
47. Saitoh, S., et al. 2000. LAT is essential for Fc(epsilon)R1-mediated mast cell activation. Immunity. 12:525-535.
48. Matsushima, K., Larsen, C.G., DuBois, G.C., and Oppenheim J.J. 1989. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J. Exp. Med. 169:1485-1490.
49. Fanslow, W.C., et al. 1994. Structural characteristics of CD40 ligand that determine biological function. Semin. Immunol. 6:267-278.
50. Tournilhac, O., et al. 2004. Excess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway [abstract]. J. Clin. Oncol. 22:6555a.
51. Campbell, J.J., et al. 1998. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science. 279:381-384.
52. De Vos, J., et al. 2001. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood. 98:771-780.
53. Vande Broek, I., et al. 2003. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br. J. Cancer. 88:855-862.
54. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
55. Masuda, A., Matsuguchi, T., Yamaki, K., Hayakawa, T., and Yoshikai, Y. 2001. Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression. J. Biol. Chem. 276:26107-26113.
56. Yuan, Q.G., Gurish, M.F., Friend, D.S., Austen, K.F., and Boyce, J.A. 1998. Generation of a novel stem cell factor-dependent mast cell progenitor. J. Immunol. 161:5143-5146.
57. Falk, L.A., Wahl, L.M., and Vogel, S.N. 1988. Analysis of 1a antigen expression in macrophages derived from bone marrow cells cultured in granulocyte-macrophage colony-stimulating factor or macrophage colony-stimulating factor. J. Immunol. 140:2652-2660.
58. Whiteland, J.L., et al. 1995. Immunohistochemical detection of T-cell subsets and other leukocytes in paraffin-embedded rat and mouse tissues with monoclonal antibodies. J. Histochem. Cytochem. 43:313-320.
59. Pawlak, G., et al. 1999. Colony-stimulating factor-1 impairs both proliferation and differentiation signals of erythropoietin during the commitment of bipotential NFS-60 cell line to the monocytic lineage. Exp. Hematol 27:797-805.
60. Pike, S.Y., et al. 1998. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J. Exp. Med. 188:2349-2356.
61. Lin, P., et al. 1997. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100:2072-2078.